$42.66
-0.63-1.46%
近くで: Sep 25, 5:00 PM EST
$42.66
N/A
時間外: 4:01 PM EST
Benzinga
Benzinga
Benzinga
土曜日, 9 26
Supernus Pharmaceuticals Inc
SUPNNASDAQ
Supernus Pharmaceuticals Earnings & Forecasts
Supernus Pharmaceuticals (SUPN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Supernus Pharmaceuticals Guidance
Supernus Pharmaceuticals (SUPN) は、8 3, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$860M - $890Mの範囲と予想しています。
以前のガイダンスと比較して、Supernus Pharmaceuticalsは売上高予測を以前の範囲である引き上げから$840M - $870Mに引き上げました。
Supernus Pharmaceuticalsは、16から11 8, 2022の間に8 3, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 6 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.42 | $0.25 | $0.22 | $0.62 |
| Actual | $0.53 | $-0.04 | $-0.07 | $-0.80 |
| Surprise | +26.2% | -116.0% | -131.8% | -229.0% |
| Revenue | ||||
| Estimate | $205.5M | $192.0M | $195.8M | $181.0M |
| Actual | $219.1M | $207.7M | $211.6M | $192.1M |
| Surprise | +6.59% | +8.17% | +8.07% | +6.16% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $0.62 | $1.02 | $0.39 |
| Revenue | |||
| Consensus | $221.3M | $238.1M | — |
Earnings & Guidance News
Benzinga
© 2026 Benzinga | All Rights Reserved